JPRN-jRCT2031220046已完成3 期
AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) - APL2-307
chendu Uchendu0 个研究点目标入组 9 人开始时间: 2022年4月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Subjects at least 18 years of age with PNH who have participated in an antecedent pegcetacoplan clinical trial. Subjects who received treatment with pegcetacoplan must have experienced clinical benefit and adequate tolerability in the opinion of the investigator.
- •Note: Subjects with PNH who completed an antecedent pegcetacoplan clinical trial without receiving pegcetacoplan (or without receiving pegcetacoplan for long enough to demonstrate clinical benefit) may be enrolled in this study if, in the opinion of the Investigator, the subject is expected to demonstrate clinical benefit upon the initiation or continuation of pegcetacoplan therapy.
- •2. Vaccination against Neisseria meningitidis types A, C, W, Y, and B, Streptococcus pneumoniae and Haemophilus influenzae type B (Hib) either within 2 years prior to Day 1 dosing of this study, or within 14 days after starting treatment with pegcetacoplan. Vaccination is mandatory unless documented evidence exists that subjects are nonresponders to vaccination as evidenced by titers or display titer levels within acceptable local limits. Immunization status checks will be performed to determine whether subjects require primary or booster vaccinations.
- •3. Willing and able to give written informed consent.
- •4. Willing and able to self-administer pegcetacoplan (administration by a caregiver will be allowed).
- •5. Women of childbearing potential, defined as any females who have experienced menarche and who are NOT permanently sterile or postmenopausal, must have a negative pregnancy test and must agree to continue to use an approved method of contraception for the duration of the study and 90 days after their last dose of study drug. Note: Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.
- •6. Males must agree to continue to use an approved method of contraception and must agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug.
排除标准
- •1. Subjects who have withdrawn from a pegcetacoplan clinical study and/or subjects who met study drug discontinuation criteria during a pegcetacoplan clinical study.
- •2. Any condition that could increase the subjects risk by participating in the study.
- •3. Any comorbidity or condition (such as malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound the study data.
- •4. History or presence of hypersensitivity or idiosyncratic reaction to compounds related to the investigational product or SC administration.
- •5. Acute or active hepatitis B, hepatitis C, or HIV infection.
- •6. Hereditary complement deficiency.
- •7. History of bone marrow transplant.
- •8. Concurrent severe aplastic anemia (defined by bone marrow cellularity <25% [or 25% to 50% if less than 30% of residual cells are hematopoietic] and at least 2 of the following values: peripheral blood absolute neutrophil count <500/micro-L [<0.5 x 109/L], peripheral blood platelet count <20,000/micro-L, peripheral blood reticulocyte count <20,000/micro-L).
- •9. History of meningococcal disease.
- •10. Concomitant treatment with any complement inhibitor (eg, eculizumab, ravulizumab).
- •11. Pregnancy, breastfeeding, or positive pregnancy test.
研究者
相似试验
已完成
不适用
APL-2 LONG-TERM SAFETY AND EFFICACY EXTENSION STUDY-D595 Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]D595PER-037-20Apellis Pharmaceuticals Inc.,
进行中（未招募）
1 期
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisEUCTR2022-002833-33-CZApellis Pharmaceuticals, Inc.100
招募中
1 期
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)MedDRA version: 20.0Level: PTClassification code: 10077827Term: C3 glomerulopathy Class: 100000004857MedDRA version: 21.1Level: LLTClassification code: 10027168Term: Membranoproliferative glomerulonephritis Class: 10038359MedDRA version: 20.0Level: SOCClassification code: 10038359Term: Renal and urinary disorders Class: 18CTIS2023-504625-39-00Apellis Pharmaceuticals Inc.125
进行中（未招募）
1 期
An Open Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long Term Safety and Efficacy of Pegcetacoplan in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).EUCTR2019-001106-23-GBApellis Pharmaceuticals, Inc.160
进行中（未招募）
1 期
An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)EUCTR2019-001106-23-BGApellis Pharmaceuticals, Inc.160